Results from a polarized Analysis of Safety Data of an adjuvanted Herpes Zoster Subunit Vaccine Candidate consisting of more than 14,500 Study Participants from the Age of 50 Years

被引：0

作者：

Lopez-Fauqued, Marta ^{[1
]}

Campora, Laura ^{[1
]}

Delannois, Frederique ^{[1
]}

El Idrissi, Mohamed ^{[1
]}

Ledent, Edouard ^{[1
]}

Diez-Domingo, Javier ^{[2
]}

McElhaney, Janet ^{[3
]}

McNeil, Shelly ^{[4
,5
]}

De Looze, Ferdinandus ^{[6
]}

Yeo, Wilfried ^{[7
]}

da Silva, Fernanda Tamares ^{[1
]}

Hain, Johannes ^{[8
]}

机构：

[1] GlaxoSmithKline, Wavre, Belgium

[2] Fdn Fomentode Invest Sanitaria & Biomed FISABIO, Valencia, Spain

[3] Hlth Sci North Res Inst, Sudbury, ON, Canada

[4] IWK Hlth Ctr, Halifax, NS, Canada

[5] Nova Scotia Hlth Author, Halifax, NS, Canada

[6] Univ Queensland, Brisbane, Qld, Australia

[7] Univ Wollongong, Wollongong, NSW, Australia

[8] GlaxoSmithKline GmbH & Co KG, Munich, Germany

来源：

INTERNIST | 2018年 / 59卷

关键词：

EFFICACY; ADULTS; OLDER;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

PS142

引用

页码：S64 / S64

页数：1

共 2 条